eOphthalmology Review
HOME       CME INFORMATION       PLANNER       NEWSLETTER ARCHIVE       EDIT PROFILE       RECOMMEND TO A COLLEAGUE
    eOphthalmology Review Volume 2 Issue 3
Title of Podcast: Neovascular AMD
After participating in this activity, the participant will demonstrate the ability to:

Develop an appropriate diagnostic assessment and initial treatment of a patient presenting with symptoms of neovascular macular degeneration
Apply the results of the pivotal phase 3 studies of ranibizumab, bevacizumab, and aflibercept to eyes with choroidal neovascular lesions
Integrate the safety results of the MARINA, ANCHOR, VIEW 1, VIEW 2, IVAN, and CATT studies into clinical practice

This discussion, offered as a downloadable audio file and companion transcript, covers the important issues related to neovascular AMD, as reported from the 2012 annual meeting of the American Academy of Ophthalmology Meeting in Chicago, Illinois. The format for this round-table discussion is case-study scenarios for the clinical practice.



Unlabeled/Unapproved Uses

The authors have indicated that this presentation will include off-label or unapproved use of the drug bevacizumab for treating neovascular macular degeneration.
Dr. Neil M. Bressler Neil M. Bressler, MD
The James P. Gills Professor of Ophthalmology
Chief, Retina Division
Wilmer Eye Institute
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr. Judy Kim Judy Kim, MD
Professor of Ophthalmology
The Eye Institute,
Medical College of Wisconsin
Milwaukee, Wisconsin
Dr. Susan Bressler Susan Bressler, MD
The Julia G. Levy PhD
Professor of Ophthalmology, Wilmer Eye Institute
Retina Division
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty Disclosures
Dr. Judy Kim discloses she has received grants and/or research support from Genentech and Regeneron.

Dr. Susan Bressler discloses that she has received grants and/or research support from Allergan, Bausch + Lomb, Genentech, Lumenis, Notal Vision, Novartis, Regeneron, and Thrombogenics. She also is a consultant advisor for GlaxoSmithKline.

Dr. Neil Bressler discloses he has received grants and/or research support from Abbott Medical Optics, Inc., Allergan, Bausch & Lomb, Bristol Myers Squibb, Carl Zeiss Meditec, ForSight Labs, LLC, Genentech, Genzyme Corporation, Lumenis, Notal Vision, Novartis Pharma AG, Optovue, Inc., Pfizer, Inc., Quark Biotech, Inc., Regeneron and Thrombogenics.


Release Date
February 14, 2013
Expiration Date
February 13, 2014

Neil M. Bressler, MD
The James P. Gills Professor of Ophthalmology
The Johns Hopkins University School of Medicine
Chief, Retina Division
Wilmer Eye Institute
Baltimore, Maryland
Susan B. Bressler, MD
The Julia G. Levy, PhD, Professor of Ophthalmology
The Johns Hopkins University School of Medicine
Wilmer Eye Institute
Baltimore, Maryland
 accreditation statements
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

credit designations
Physicians: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Each podcast is certified for .75 credits.

internet cme policy
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. The Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public.

Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the accredited provider's CME program. CME collects only the information necessary to provide you with the services that you request

launch date
October 25, 2012; activities expire 1 year from the date of publication.

statement of responsibility
The Johns Hopkins University School of Medicine take responsibility for the content, quality and scientific integrity of this CME activity.

intended audience
The activity has been developed for ophthalmologists and retina specialists.

There are no fees or prerequisites to participate.

Estimated time to complete activity: 45 minutes.

disclaimer statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

PLANNER disclosures
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education requires the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The course director and planning committee reported the following:

Neil M. Bressler, MD has disclosed he has received grants/ research support from Abbott Medical Optics, Inc., Allergan, Bausch & Lomb, Bristol Myers Squibb, Carl Zeiss Meditec, ForSight Labs, LLC., Genentech, Genzyme Corporation, Lumenis, Notal Vision, Novartis, Optovue, Inc., Pfizer, Inc., Quark Biotech, Inc., and Regeneron. His spouse has served as a consultant for GlaxoSmithKline and has received grants and/or research support from Allergan, Bausch & Lomb, Genentech, Lumenis, Notal Vision, Novartis, Regeneron, and Thrombogenics.
Susan Bressler, MD has disclosed that she has served as a consultant for GlaxoSmithKline, and also has received grant/research support form Allergan, Bausch & Lomb, Genentech, Lumenis, Notal Vision, Novartis, Regeneron and Thrombogenics.
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Guest Author Disclosures




CONFIDENTIALITY DISCLAIMER FOR CME CONFERENCE ATTENDEES
I certify that I am attending a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

"The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only."

For CME Questions, please contact the CME Office at (410) 955-2959 or e-mail cmenet@jhmi.edu.
For CME Certificates, please call (410) 502-9634.

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195

Reviewed & Approved by:
General Counsel, Johns Hopkins Medicine (4/1/03)
Updated 4/09


successful completion
To successfully complete this activity, participants must read the content, then link to the Johns Hopkins University School of Medicine's CME website to complete the post-test with a passing grade, and complete the evaluation. Once you receive a passing grade, you can access and print your certificate of credit.

STATEMENT OF NEED:
The treatment of retinal diseases is an area of medicine where research and innovation are very strong. Newly presented information-and information due to come out very soon-will very likely change the ways clinicians provide optimal patient care. Many of these new trial results have not yet been published; the initial findings of much of the most important new data were first made public at key ophthalmology and retina specialist meetings in 2011. Trial updates, initial findings from ongoing trials, and guidance translating this critical information into practice protocols are expected to be presented at similar meetings throughout 2012.

Clinicians are either not aware of this new information and/or are not sure how they can best integrate it into their practices. Four key (interrelated) retinal treatment areas where increased clinician awareness will provide the most immediate patient benefit have been identified by the program directors.

RETINAL VEIN OCCLUSION: New retinal vein occlusion treatment approaches have created uncertainty about choosing the most appropriate therapeutic option.
MACULAR DEGENERATION: Newly released data may herald significant changes in the treatment of AMD that clinicians are unprepared to implement.
DIABETIC RETINOPATHY/DIABETIC MACULAR EDEMA: Integrating ongoing research likely to change current diabetic retinopathy/diabetic macular edema treatment protocols has led to clinician confusion about best practices.
VITREOMACULAR ADHESION: Clinician unfamiliarity with therapies currently in development may delay delivery of optimum benefit for patients with vitreomacular adhesion.
Listen to podcast now
If you want to now listen to the eOphthalmology Review podcast, just click on the button above. This will open your Internet browser to play the podcast by streaming the media via the web.

Please note: This podcast file is large so please be patient while the content downloads.
Download podcast
Save the podcast to your computer. Once saved you can manage and play the file like any song or music using your music software (iTunes, Windows Media, Real Player, etc.). You can also transfer the podcast file to your iPod, MP3 player and listen while on-the-go.
Subscribe to eOphthalmology Review
Like any RSS subscription,
when you subscribe to
eOphthalmology Review you will automatically receive each new edition, downloaded to your hard drive as soon as it becomes available. You may manage and play the downloaded podcast file like any song or audio file by using your music software (iTunes, Windows Media, Real Player, etc.). You can also transfer the podcast file to your iPod, MP3 player to listen while on-the-go.
Subscribe to eOphthalmology Review
COMPLETE THE
POST-TEST


Step 1. Click on the appropriate link below. This will take you to the post-test.

Step 2. If you have participated in a Johns Hopkins on-line course, login. Otherwise, please register.

Step 3. Complete the post-test and course evaluation.

Step 4. Print out your certificate.
eOphthalmology Review Newsletter Archive
»Download the podcast transcript
»Learn more about podcasting
Help other ophthalmologists find solutions to the diagnosis and treatment of retinal diseases. Forward a link to the eOphthalmology Review website to a colleague.
© 2013 JHUSOM and eOphthalmology Review

Presented by JHUSOM in collaboration with DKBmed.